Evidence map›Paper›PMID 30718813›Full record

ArticleNature chemical biology2019

A chemoproteomic portrait of the oncometabolite fumarate.

Rhushikesh A Kulkarni, Daniel W Bak, Darmood Wei, Sarah E Bergholtz, Chloe A Briney, Jonathan H Shrimp, Aktan Alpsoy, Abigail L Thorpe, Arissa E Bavari, Daniel R Crooks and 8 more

Abstract read
In one paragraph

Article in Nature chemical biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Citric Acid Cycle Genes and Nutrigenetics.International journal of molecular sciences · 2026
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Regulation of airway fumarate by host and pathogen promotesbioRxiv : the preprint server for biology · 2025
    Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rhushikesh A KulkarniChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MA, USA.
Daniel W BakDepartment of Chemistry, Boston College, Chestnut Hill, MA, USA.
Darmood WeiUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MA, USA.
Sarah E BergholtzChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MA, USA.
Chloe A BrineyChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MA, USA.
Jonathan H ShrimpChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MA, USA.ORCID http://orcid.org/0000-0001-9872-942X
Aktan AlpsoyDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA.
Abigail L ThorpeChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MA, USA.
Arissa E BavariChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MA, USA.
Daniel R CrooksUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MA, USA.
Michaella LevyStowers Institute for Medical Research, Kansas City, MI, USA.
Laurence FlorensStowers Institute for Medical Research, Kansas City, MI, USA.
Michael P WashburnStowers Institute for Medical Research, Kansas City, MI, USA.ORCID http://orcid.org/0000-0001-7568-2585
Norma FrizzellDepartment of Pharmacology, Physiology and Neuroscience, School of Medicine, University of South Carolina, Columbia, SC, USA.
Emily C DykhuizenDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA.
Eranthie WeerapanaDepartment of Chemistry, Boston College, Chestnut Hill, MA, USA.
W Marston LinehanUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MA, USA.
Jordan L MeierChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MA, USA. jordan.meier@nih.gov.ORCID http://orcid.org/0000-0002-0537-7101

Funding

Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase GeneZIABC011038 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$29.8M
Targeting Cancer Through Modifications and MetabolismZIABC011488 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MEIER, JORDAN L · 2013 to 2025
$21.3M
Investigating cysteine-mediated protein activities in C. elegansR01GM118431 · NIGMS · BOSTON COLLEGE · PI WEERAPANA, ERANTHIE · 2015 to 2019
$1.8M
The tumor suppressive role of PBRM1, the bromodomain-containing subunit of the PBAF chromatin remodeling complexU01CA207532 · NCI · PURDUE UNIVERSITY · PI DYKHUIZEN, EMILY CARLA · 2017 to 2021
$1.7M
Investigating cysteine PTMs in living cellsR01GM117004 · NIGMS · BOSTON COLLEGE · PI WEERAPANA, ERANTHIE · 2016 to 2019
$1.2M
Protein Succination as a Mediator of Neuropathology in Mitochondrial DiseaseR01NS092938 · NINDS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI FRIZZELL, NORMA · 2015 to 2018
$887k
Intramural NIH HHS ZIA BC011038Intramural NIH HHS ZIA BC011488NCI NIH HHS U01 CA207532NIGMS NIH HHS R01 GM117004NIGMS NIH HHS R01 GM118431NINDS NIH HHS R01 NS092938
6 · The paper itself

Abstract

Hereditary cancer disorders often provide an important window into novel mechanisms supporting tumor growth. Understanding these mechanisms thus represents a vital goal. Toward this goal, here we report a chemoproteomic map of fumarate, a covalent oncometabolite whose accumulation marks the genetic cancer syndrome hereditary leiomyomatosis and renal cell carcinoma (HLRCC). We applied a fumarate-competitive chemoproteomic probe in concert with LC-MS/MS to discover new cysteines sensitive to fumarate hydratase (FH) mutation in HLRCC cell models. Analysis of this dataset revealed an unexpected influence of local environment and pH on fumarate reactivity, and enabled the characterization of a novel FH-regulated cysteine residue that lies at a key protein-protein interface in the SWI-SNF tumor-suppressor complex. Our studies provide a powerful resource for understanding the covalent imprint of fumarate on the proteome and lay the foundation for future efforts to exploit this distinct aspect of oncometabolism for cancer diagnosis and therapy.

Indexed as

Cell Line, TumorChromatography, LiquidCysteineFumaratesHEK293 CellsHumansHydrogen-Ion ConcentrationLeiomyomatosisModels, BiologicalNeoplastic Syndromes, HereditaryProteomicsSignal TransductionSkin NeoplasmsTandem Mass SpectrometryUterine NeoplasmsCysteineFumarates

Identifiers

PMID30718813
PMCPMC6430658

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.